董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Firdaus Jal Dastoor | 男 | Independent Director | 72 | 5.17万美元 | 未持股 | 2025-12-11 |
| Roger Kornberg | 男 | Independent Director | 77 | 5.17万美元 | 未持股 | 2025-12-11 |
| Dmitry Genkin | 男 | Chairman | 56 | 未披露 | 未持股 | 2025-12-11 |
| Moshe Mizrahy | 男 | Director | 72 | 未披露 | 未持股 | 2025-12-11 |
| Grigory Borisenko | 男 | Independent Director | 56 | 5.17万美元 | 未持股 | 2025-12-11 |
| Alexey Vinogradov | 男 | Independent Director | 55 | 5.17万美元 | 未持股 | 2025-12-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James Parslow | 男 | Interim Chief Executive Officer, Chief Financial Officer and Corporate Secretary | 59 | 48.12万美元 | 未持股 | 2025-12-11 |
董事简历
中英对照 | 中文 | 英文- Firdaus Jal Dastoor
-
Firdaus Jal Dastoor自2014年1月起担任公司董事，符合公司收购Xenetic U.K。 的条例要求。Dastoor于2007年7月被任命为Xenetic U.K。 非执行董事。他自2008年起担任The Institute of Company Secretaries of India研究员。他一直担任Poonawalla Group公司秘书到1994年。后来他接手业务开发战略和运营任务，包括Serum Institute, Eureka Finvest Pvt, Ltd, EagleBurgmann India Pvt, Ltd. And PPCE Pvt, Ltd.Dastoor现任多个公司（工程产品、生命科学和生物技术、国际贸易、金融服务和质量标准认证）董事。如今他担任Poonawalla Group of Companies集团主管，负责金融和企业事务。
Firdaus Jal Dastoor has served as a member of Board since January 2014 pursuant to terms of the agreement of acquisition of Xenetic U.K. He has been employed by the Cyr Poonawalla Group, a conglomerate in India with interests in horse breeding, biotech and life sciences, and financial services, in biness development strategies and operational roles since October 1981. Mr. Dastoor is currently a Group Director in charge of Finance and Corporate Affairs and Company Secretary of the Serum Institute of India Private Limited at the Cyr Poonawalla Group. He has been a Fellow Member of The Institute of Company Secretaries of India since 1990. Mr. Dastoor is on the board of several private companies operating in the fields of life sciences and biotech, international trade, financial services and quality standards certifications. Mr. Dastoor received a B.A. in Commerce from the University of Poona. - Firdaus Jal Dastoor自2014年1月起担任公司董事，符合公司收购Xenetic U.K。 的条例要求。Dastoor于2007年7月被任命为Xenetic U.K。 非执行董事。他自2008年起担任The Institute of Company Secretaries of India研究员。他一直担任Poonawalla Group公司秘书到1994年。后来他接手业务开发战略和运营任务，包括Serum Institute, Eureka Finvest Pvt, Ltd, EagleBurgmann India Pvt, Ltd. And PPCE Pvt, Ltd.Dastoor现任多个公司（工程产品、生命科学和生物技术、国际贸易、金融服务和质量标准认证）董事。如今他担任Poonawalla Group of Companies集团主管，负责金融和企业事务。
- Firdaus Jal Dastoor has served as a member of Board since January 2014 pursuant to terms of the agreement of acquisition of Xenetic U.K. He has been employed by the Cyr Poonawalla Group, a conglomerate in India with interests in horse breeding, biotech and life sciences, and financial services, in biness development strategies and operational roles since October 1981. Mr. Dastoor is currently a Group Director in charge of Finance and Corporate Affairs and Company Secretary of the Serum Institute of India Private Limited at the Cyr Poonawalla Group. He has been a Fellow Member of The Institute of Company Secretaries of India since 1990. Mr. Dastoor is on the board of several private companies operating in the fields of life sciences and biotech, international trade, financial services and quality standards certifications. Mr. Dastoor received a B.A. in Commerce from the University of Poona.
- Roger Kornberg
-
Roger Kornberg自2016年2月起担任公司董事。Kornberg是U.S. National Academy of Sciences成员；Stanford University结构生物学专业医学Winzer教授。他于1967年获得Harvard University化学学士学位；1972年获得Stanford化学物理学博士学位。他是英国坎布里奇Laboratory of Molecular Biology博士后研究员；1976年成为Harvard Medical School生物化学助理教授；1978年成为Stanford Medical School结构生物学教授。2006年Kornberg被授予诺贝尔化学奖，因其对真核基因转录（DNA被复制到RNA的过程）微生物的研究而获此殊荣。Kornberg还是多个奖项的获得者，包括2001年Welch Prize（美国化学领域最高奖项）；2002年Leopald Mayer Prize（法官生物医疗科学领域最高奖项）。
Roger Kornberg, PhD has served as a member of Board since February 2016. Dr. Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. He earned his B.S. in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972. He became a postdoctoral fellow at the Laboratory of Molecular Biology in Cambridge, England and then an assistant professor of biological chemistry at Harvard Medical School in 1976, before moving to his present position as professor of structural biology at Stanford Medical School in 1978. In 2006, Dr. Kornberg was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular basis of Eukaryotic Transcription, the process by which DNA is copied to RNA. Dr. Kornberg is also the recipient of several awards, including the 2001 lch Prize, the highest award granted in the field of chemistry in the United States, and the 2002 Leopald Mayer Prize, the highest award granted in the field of biomedical sciences from the French Academy of Sciences. Dr. Kornberg has served as a director of Cocrystal Pharma, Inc. (NasdaqCM: COCP) since April 2020. - Roger Kornberg自2016年2月起担任公司董事。Kornberg是U.S. National Academy of Sciences成员；Stanford University结构生物学专业医学Winzer教授。他于1967年获得Harvard University化学学士学位；1972年获得Stanford化学物理学博士学位。他是英国坎布里奇Laboratory of Molecular Biology博士后研究员；1976年成为Harvard Medical School生物化学助理教授；1978年成为Stanford Medical School结构生物学教授。2006年Kornberg被授予诺贝尔化学奖，因其对真核基因转录（DNA被复制到RNA的过程）微生物的研究而获此殊荣。Kornberg还是多个奖项的获得者，包括2001年Welch Prize（美国化学领域最高奖项）；2002年Leopald Mayer Prize（法官生物医疗科学领域最高奖项）。
- Roger Kornberg, PhD has served as a member of Board since February 2016. Dr. Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. He earned his B.S. in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972. He became a postdoctoral fellow at the Laboratory of Molecular Biology in Cambridge, England and then an assistant professor of biological chemistry at Harvard Medical School in 1976, before moving to his present position as professor of structural biology at Stanford Medical School in 1978. In 2006, Dr. Kornberg was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular basis of Eukaryotic Transcription, the process by which DNA is copied to RNA. Dr. Kornberg is also the recipient of several awards, including the 2001 lch Prize, the highest award granted in the field of chemistry in the United States, and the 2002 Leopald Mayer Prize, the highest award granted in the field of biomedical sciences from the French Academy of Sciences. Dr. Kornberg has served as a director of Cocrystal Pharma, Inc. (NasdaqCM: COCP) since April 2020.
- Dmitry Genkin
-
Dmitry Genkin于2017年8月14日被任命为董事会成员。Genkin博士此前曾于2004年至2016年在公司董事会任职。1992年至1993年，他在伦敦大学药学院Gregory Gregoriadis教授指导下学习药物输送，1992年至1993年在斯德哥尔摩卡罗林斯卡医院临床药理系学习。Genkin自2005年起担任PJSC Pharmsynthez（一家上市公司，Xenetic重要股东）执行董事长。在此之前，Genkin博士领导了许多俄罗斯最大的制药公司，包括Pharmavit，俄罗斯制药市场的大型参与者。1998年，他被俄罗斯自然科学学院授予银质奖章。
Dmitry Genkin, MD has served as a current member of Board since December 2023. Dr. Genkin previoly served on the Company's Board of Directors from 2017 2021. He studied drug delivery under Professor Gregory Gregoriadis at The School of Pharmacy, University of London, as ll as at the Department of Clinical Pharmacology at Karolinska Hospital, Stockholm. Since 2005, Dr. Genkin has served as Executive Chairman of PJSC Pharmsynthez, a stockholder of Xenetic. Dr. Genkin is founder and board member of Santers AG – a Swiss private therapeutic medical device company developing novel apheresis therapies for extracorporeal removal of NETs. Dr. Genkin is on the board of CLS Therapeutics Inc. and Peri Ness Ltd. – private biotechnology companies developing anti NETosis therapies. Dr. Genkin is the inventor of more than 20 patents and patent applications in the field of therapeutics targeting of NETosis and cell free DNA. - Dmitry Genkin于2017年8月14日被任命为董事会成员。Genkin博士此前曾于2004年至2016年在公司董事会任职。1992年至1993年，他在伦敦大学药学院Gregory Gregoriadis教授指导下学习药物输送，1992年至1993年在斯德哥尔摩卡罗林斯卡医院临床药理系学习。Genkin自2005年起担任PJSC Pharmsynthez（一家上市公司，Xenetic重要股东）执行董事长。在此之前，Genkin博士领导了许多俄罗斯最大的制药公司，包括Pharmavit，俄罗斯制药市场的大型参与者。1998年，他被俄罗斯自然科学学院授予银质奖章。
- Dmitry Genkin, MD has served as a current member of Board since December 2023. Dr. Genkin previoly served on the Company's Board of Directors from 2017 2021. He studied drug delivery under Professor Gregory Gregoriadis at The School of Pharmacy, University of London, as ll as at the Department of Clinical Pharmacology at Karolinska Hospital, Stockholm. Since 2005, Dr. Genkin has served as Executive Chairman of PJSC Pharmsynthez, a stockholder of Xenetic. Dr. Genkin is founder and board member of Santers AG – a Swiss private therapeutic medical device company developing novel apheresis therapies for extracorporeal removal of NETs. Dr. Genkin is on the board of CLS Therapeutics Inc. and Peri Ness Ltd. – private biotechnology companies developing anti NETosis therapies. Dr. Genkin is the inventor of more than 20 patents and patent applications in the field of therapeutics targeting of NETosis and cell free DNA.
- Moshe Mizrahy
-
Moshe Mizrahy于2008年共同创立了该公司，自成立以来一直担任我们的首席执行官兼董事会主席。在此之前，Mizrahy先生是Syneron MedicalLtd.公司（一家位于以色列的医疗美容设备公司）的联合创始人兼首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，该公司是一家活跃于家庭使用市场的国际医疗美容消费设备公司，目前自2007年起担任其董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前担任以下公司的董事会成员:Sipnose Ltd.、Pet Novations Ltd.、Peri-ness Technologies Ltd.、Easy-Lap Ltd、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、New Forest Wood Products-2012Ltd.，M.N.Business Strategy Ltd.、Himalaya Family Office Advisory Ltd.和Polimer Logistics Israel Ltd.Mizrahy先生在特拉维夫大学（Tel Aviv University）获得工程学学士学位，并在纽约佩斯大学（Pace University）获得工商管理硕士学位。
Moshe Mizrahy has served as a member of Board since December 2023. Mr. Mizrahy is co founder of InMode Ltd. (NASDAQ: INMD) and has served as its Chief Executive Officer and Chairman of its board of directors since its inception in 2008. Prior to that, Mr. Mizrahy was co founder and chief executive officer of Syneron Medical Ltd. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd., and is currently chairman of its board. In addition to Home Skinovations Ltd., Mr. Mizrahy currently sits on the board of directors of SipNose Ltd., Pet Novations Ltd., Peri Ness Technologies Ltd., Santers AG, Easy Lap Ltd., O.B. Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., M.N. Biness Strategy Ltd., Silk'n Cure Ltd., Himalaya Family Office Advising Ltd. and Polimer Logistics (Israel) Ltd. Mr. Mizrahy is co founder and general partner of Nitzanim AVX Kyocera Venture Capital Fund and First Israel Mezzeine Investors Fund. Mr. Mizrahy has expertise in value creation for medical technologies, fundraising, public offerings, marketing and regulatory affairs. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York. - Moshe Mizrahy于2008年共同创立了该公司，自成立以来一直担任我们的首席执行官兼董事会主席。在此之前，Mizrahy先生是Syneron MedicalLtd.公司（一家位于以色列的医疗美容设备公司）的联合创始人兼首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，该公司是一家活跃于家庭使用市场的国际医疗美容消费设备公司，目前自2007年起担任其董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前担任以下公司的董事会成员:Sipnose Ltd.、Pet Novations Ltd.、Peri-ness Technologies Ltd.、Easy-Lap Ltd、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、New Forest Wood Products-2012Ltd.，M.N.Business Strategy Ltd.、Himalaya Family Office Advisory Ltd.和Polimer Logistics Israel Ltd.Mizrahy先生在特拉维夫大学（Tel Aviv University）获得工程学学士学位，并在纽约佩斯大学（Pace University）获得工商管理硕士学位。
- Moshe Mizrahy has served as a member of Board since December 2023. Mr. Mizrahy is co founder of InMode Ltd. (NASDAQ: INMD) and has served as its Chief Executive Officer and Chairman of its board of directors since its inception in 2008. Prior to that, Mr. Mizrahy was co founder and chief executive officer of Syneron Medical Ltd. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd., and is currently chairman of its board. In addition to Home Skinovations Ltd., Mr. Mizrahy currently sits on the board of directors of SipNose Ltd., Pet Novations Ltd., Peri Ness Technologies Ltd., Santers AG, Easy Lap Ltd., O.B. Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., M.N. Biness Strategy Ltd., Silk'n Cure Ltd., Himalaya Family Office Advising Ltd. and Polimer Logistics (Israel) Ltd. Mr. Mizrahy is co founder and general partner of Nitzanim AVX Kyocera Venture Capital Fund and First Israel Mezzeine Investors Fund. Mr. Mizrahy has expertise in value creation for medical technologies, fundraising, public offerings, marketing and regulatory affairs. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York.
- Grigory Borisenko
-
Grigory Borisenko于2019年9月被任命为董事会成员。Borisenko先生是Rusnano Management Company LLC的投资总监，这是一家俄罗斯的风险投资&私募股权管理公司。Borisenko先生在生命科学领域拥有超过20年的科学、管理和战略经验。Borisenko先生自2012年以来一直专注于生命科学的投资项目，从2009年到2012年，他是the State Corporation，Rusnano科学和技术部的制药部门主管。Borisenko先生目前在两家生物技术公司ATEA Pharmaceuticals，Inc.和Adastra Pharmaceuticals，Inc.的董事会任职，并于2011年至2014年在NearMedic Pharm LLC的董事会任职。在他的投资生涯之前，Borisenko先生在匹兹堡大学（University of Pittsburgh），俄罗斯国立医科大学（Russian State Medical University）和医学生物问题研究所（Institute of Medico-Biological Problems）担任学术职务。他在领先的生物化学和细胞生物学期刊上共同撰写了50多篇同行评议的出版物。Borisenko先生在俄罗斯国立医科大学（Russian State Medical University）获得硕士学位和博士学位，并且是Fogarty International和NIH的国际奖学金获得者。
Grigory Borisenko has served as a member of Board since 2019. Dr. Borisenko has over 25 years of scientific, management and strategic experience in the life science field. Since April 2022, Dr. Borisenko has been an independent consultant for a number of companies. Prior to that time, Dr. Borisenko served as an Investment Director of an eastern European venture capital and private equity management fund, and has specialized in investment projects in life sciences for over ten years. Dr. Borisenko served on the board of directors of multiple biotechnology companies including Atea Pharmaceuticals, Inc. and Adastra Pharmaceuticals, Inc. Currently, Dr. Borisenko provides consulting and investment advising services in the biotech area. Prior to his investment career, Dr. Borisenko held academic appointments with the University of Pittsburgh and co authored over fifty peer revied publications in leading biochemistry and cell biology jnals. Dr. Borisenko received his M.S. and Ph.D. from the Pirogov State Medical University, accomplished postdoctoral training at the University of Pittsburg and is a recipient of Fogarty International and International Fellowship Awards from NIH and WHO. - Grigory Borisenko于2019年9月被任命为董事会成员。Borisenko先生是Rusnano Management Company LLC的投资总监，这是一家俄罗斯的风险投资&私募股权管理公司。Borisenko先生在生命科学领域拥有超过20年的科学、管理和战略经验。Borisenko先生自2012年以来一直专注于生命科学的投资项目，从2009年到2012年，他是the State Corporation，Rusnano科学和技术部的制药部门主管。Borisenko先生目前在两家生物技术公司ATEA Pharmaceuticals，Inc.和Adastra Pharmaceuticals，Inc.的董事会任职，并于2011年至2014年在NearMedic Pharm LLC的董事会任职。在他的投资生涯之前，Borisenko先生在匹兹堡大学（University of Pittsburgh），俄罗斯国立医科大学（Russian State Medical University）和医学生物问题研究所（Institute of Medico-Biological Problems）担任学术职务。他在领先的生物化学和细胞生物学期刊上共同撰写了50多篇同行评议的出版物。Borisenko先生在俄罗斯国立医科大学（Russian State Medical University）获得硕士学位和博士学位，并且是Fogarty International和NIH的国际奖学金获得者。
- Grigory Borisenko has served as a member of Board since 2019. Dr. Borisenko has over 25 years of scientific, management and strategic experience in the life science field. Since April 2022, Dr. Borisenko has been an independent consultant for a number of companies. Prior to that time, Dr. Borisenko served as an Investment Director of an eastern European venture capital and private equity management fund, and has specialized in investment projects in life sciences for over ten years. Dr. Borisenko served on the board of directors of multiple biotechnology companies including Atea Pharmaceuticals, Inc. and Adastra Pharmaceuticals, Inc. Currently, Dr. Borisenko provides consulting and investment advising services in the biotech area. Prior to his investment career, Dr. Borisenko held academic appointments with the University of Pittsburgh and co authored over fifty peer revied publications in leading biochemistry and cell biology jnals. Dr. Borisenko received his M.S. and Ph.D. from the Pirogov State Medical University, accomplished postdoctoral training at the University of Pittsburg and is a recipient of Fogarty International and International Fellowship Awards from NIH and WHO.
- Alexey Vinogradov
-
Alexey Vinogradov自2019年7月起担任董事会成员。Vinogradov博士目前担任Cantreva LLC的业务开发总监兼运营总监，该公司是一家俄罗斯公司，具有在可再生能源太阳能，风能，水力发电领域提供服务的丰富专业经验，自2017年9月起在交钥匙基础上进行工作。Vinogradov博士此前于2015年5月至2017年5月担任阿联酋迪拜Togas Middle East LLC的总经理。在此之前，Vinogradov博士于2012年3月至2016年11月担任俄罗斯Togas Group LLC的分公司经理。
Alexey Vinogradov has served as a member of Board since July 2019. Dr. Vinogradov currently works as Biness Development Manager at Mag. Peter G. Wahl's Law Firm in Vienna, Atria, which foces on corporate, property and commercial law. Dr. Vinogradov has extensive experience in biness development. From 2017 to 2022 he worked as a Biness Development Director and Operations Director at Cantreva LLC, providing services in the field of renewable energy sces (solar, wind, hydropor). Previoly, from 2015 to 2017, Dr. Vinogradov held the executive position at Togas Middle East LLC in Dubai, UAE. Dr. Vinogradov is a member of the board of PJSC Pharmsynthez a shareholder of Xenetic. - Alexey Vinogradov自2019年7月起担任董事会成员。Vinogradov博士目前担任Cantreva LLC的业务开发总监兼运营总监，该公司是一家俄罗斯公司，具有在可再生能源太阳能，风能，水力发电领域提供服务的丰富专业经验，自2017年9月起在交钥匙基础上进行工作。Vinogradov博士此前于2015年5月至2017年5月担任阿联酋迪拜Togas Middle East LLC的总经理。在此之前，Vinogradov博士于2012年3月至2016年11月担任俄罗斯Togas Group LLC的分公司经理。
- Alexey Vinogradov has served as a member of Board since July 2019. Dr. Vinogradov currently works as Biness Development Manager at Mag. Peter G. Wahl's Law Firm in Vienna, Atria, which foces on corporate, property and commercial law. Dr. Vinogradov has extensive experience in biness development. From 2017 to 2022 he worked as a Biness Development Director and Operations Director at Cantreva LLC, providing services in the field of renewable energy sces (solar, wind, hydropor). Previoly, from 2015 to 2017, Dr. Vinogradov held the executive position at Togas Middle East LLC in Dubai, UAE. Dr. Vinogradov is a member of the board of PJSC Pharmsynthez a shareholder of Xenetic.
高管简历
中英对照 | 中文 | 英文- James Parslow
James Parslow于2017年4月3日，被任命为Xenetic Biosciences, Inc.首席财务官。Parslow先生最近于2006年担任World Energy Solutions，Inc.的首席财务官、财务主管兼秘书，该公司是一家公开上市的企业对企业电子商务公司，从事能源和环境商品经纪业务，直至2015年被EnerNOC，Inc.收购。从2015年到2017年，他担任独立顾问，为多家新兴科技公司提供临时首席财务官服务。Parslow先生是一名注册会计师，在生物技术、清洁技术、电子商务和高科技制造行业为私营和上市公司服务超过35年。他拥有圣十字学院经济学和会计学学士学位和本特利大学金融学硕士学位。
James Parslow was appointed interim Chief Executive Officer on May 16, 2024, and has served as Chief Financial Officer since April 3, 2017. Mr. Parslow most recently served as Chief Financial Officer, Treasurer and Secretary of World Energy Solutions, Inc., a publicly traded biness to biness e commerce company brokering energy and environmental commodities, from 2006 until its acquisition by EnerNOC, Inc. in 2015. From 2015 until 2017, he served as an independent consultant providing interim chief financial officer services to multiple emerging technology companies. Mr. Parslow is a Certified Public Accountant with over 35 years of experience serving private and public companies in the biotech, clean tech, e commerce, and high tech manufacturing indtries. He holds an A.B. in Economics and Accounting from the College of the Holy Cross and an M.B.A. with a concentration in Finance from Bentley University.- James Parslow于2017年4月3日，被任命为Xenetic Biosciences, Inc.首席财务官。Parslow先生最近于2006年担任World Energy Solutions，Inc.的首席财务官、财务主管兼秘书，该公司是一家公开上市的企业对企业电子商务公司，从事能源和环境商品经纪业务，直至2015年被EnerNOC，Inc.收购。从2015年到2017年，他担任独立顾问，为多家新兴科技公司提供临时首席财务官服务。Parslow先生是一名注册会计师，在生物技术、清洁技术、电子商务和高科技制造行业为私营和上市公司服务超过35年。他拥有圣十字学院经济学和会计学学士学位和本特利大学金融学硕士学位。
- James Parslow was appointed interim Chief Executive Officer on May 16, 2024, and has served as Chief Financial Officer since April 3, 2017. Mr. Parslow most recently served as Chief Financial Officer, Treasurer and Secretary of World Energy Solutions, Inc., a publicly traded biness to biness e commerce company brokering energy and environmental commodities, from 2006 until its acquisition by EnerNOC, Inc. in 2015. From 2015 until 2017, he served as an independent consultant providing interim chief financial officer services to multiple emerging technology companies. Mr. Parslow is a Certified Public Accountant with over 35 years of experience serving private and public companies in the biotech, clean tech, e commerce, and high tech manufacturing indtries. He holds an A.B. in Economics and Accounting from the College of the Holy Cross and an M.B.A. with a concentration in Finance from Bentley University.